Efficacy of abrocitinib monotherapy for the treatment of moderate-to-severe atopic dermatitis by race

被引：0

作者：

Alexis, A. F. ^{[1
]}

Silverberg, J. I. ^{[2
]}

Rice, Z. P. ^{[3
]}

Armstrong, A. W. ^{[4
]}

Desai, S. R. ^{[5
,6
]}

Fonacier, L. ^{[7
]}

Kabashima, K. ^{[8
]}

Levenberg, M. ^{[9
]}

Biswas, P. ^{[9
]}

Cella, R. Rojo ^{[10
]}

Chan, G. L. ^{[10
]}

机构：

[1] Weill Cornell Med Coll, New York, NY USA

[2] George Washington Univ, Sch Med & Hlth Sci, Washington, DC 20052 USA

[3] Dermatol Associates Georgia, Atlanta, GA USA

[4] Univ Southern Calif, Keck Sch Med, Los Angeles, CA 90007 USA

[5] Innovat Dermatol, Plano, TX USA

[6] Univ Texas Southwestern Med Ctr Dallas, Dallas, TX 75390 USA

[7] NYU Langone Hosp Long Isl, Mineola, NY USA

[8] Kyoto Univ, Kyoto, Japan

[9] Pfizer Inc, New York, NY USA

[10] Pfizer Inc, Groton, CT 06340 USA

来源：

BRITISH JOURNAL OF DERMATOLOGY | 2021年 / 185卷 / 03期

关键词：

D O I：

暂无

中图分类号：

R75 [皮肤病学与性病学];

学科分类号：

100206 ;

摘要：

516

引用

页码：E137 / E138

页数：2

共 50 条

[1] Abrocitinib for the Treatment of Moderate-to-Severe Atopic Dermatitis
Villegas, Susan C.
Dima, Lorena
AMERICAN JOURNAL OF THERAPEUTICS, 2023, 30 (02) : E117 - E125
[2] Abrocitinib: a potential treatment for moderate-to-severe atopic dermatitis
Nezamololama, Novin
Crowley, Erika L.
Gooderham, Melinda J.
Papp, Kim
EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2020, 29 (09) : 911 - 917
[3] An evaluation of abrocitinib for moderate-to-severe atopic dermatitis
Labib, Angelina
Yosipovitch, Gil
EXPERT REVIEW OF CLINICAL IMMUNOLOGY, 2022, 18 (11) : 1107 - 1118
[4] Abrocitinib efficacy and safety in moderate-to-severe atopic dermatitis by race, ethnicity, and Fitzpatrick skin type
Alexis, Andrew F.
Silverberg, Jonathan I.
Rice, Zakiya P.
Armstrong, April W.
Desai, Seemal R.
Fonacier, Luz
Kabashima, Kenji
Biswas, Pinaki
Cella, Ricardo Rojo
Chan, Gary L.
Levenberg, Mark
ANNALS OF ALLERGY ASTHMA & IMMUNOLOGY, 2024, 132 (03) : 383 - 389.e3
[5] Integrated Efficacy and Safety Analysis of Abrocitinib in Adolescents With Moderate-to-Severe Atopic Dermatitis
Paller, Amy S.
Eichenfield, Lawrence F.
Irvine, Alan D.
Flohr, Carsten
Wollenberg, Andreas
Barbarot, Sebastien
Bangert, Christine
Spergel, Jonathan M.
Selfridge, Andrew
Biswas, Pinaki
Fan, Haiyun
Alderfer, Justine
Watkins, Melissa
Koppensteiner, Herwig
ALLERGY, 2025,
[6] Efficacy and safety of abrocitinib in patients with moderate-to-severe atopic dermatitis and comorbid allergies
Schmid-Grendelmeier, Peter
Gooderham, Melinda J.
Hartmann, Karin
Konstantinou, George N.
Fellmann, Marc
Koulias, Christopher
Clibborn, Claire
Biswas, Pinaki
Brunner, Patrick M.
ALLERGY, 2024, 79 (01) : 174 - 183
[7] EFFICACY AND SAFETY OF ABROCITINIB MONOTHERAPY IN ADULTS AND ADOLESCENTS WITH MODERATE-TO-SEVERE ATOPIC DERMATITIS: A POST HOC ANALYSIS OF JADE REGIMEN
Flohr, Carsten
Cork, Michael J.
Eichenfield, Lawrence F.
Feeney, Claire
Koppersteiner, Herwig
Lazariciu, Irina
Nesnas, John
ACTA DERMATO-VENEREOLOGICA, 2022, 102 : 31 - 31
[8] Abrocitinib, tralokinumab and upadacitinib for treating moderate-to-severe atopic dermatitis
Edwards, Steven J.
Karner, Charlotta
Jhita, Tracey
Barton, Samantha
Marceniuk, Gemma
Yiu, Zenas Z. N.
Wittmann, Miriam
HEALTH TECHNOLOGY ASSESSMENT, 2024, 28 (04)
[9] Efficacy of Abrocitinib for the Treatment of Moderate-to-Severe Atopic Dermatitis in Real-World Practice in a Single Center
Bai, Juan
Su, Wang
Fang, Hong
Qiao, Jianjun
AMERICAN JOURNAL OF THERAPEUTICS, 2024, 31 (03) : e332 - e334
[10] Efficacy and Safety of Abrocitinib in Patients With Moderate-to-Severe Atopic Dermatitis A Randomized Clinical Trial
Silverberg, Jonathan, I
Simpson, Eric L.
Thyssen, Jacob P.
Gooderham, Melinda
Chan, Gary
Feeney, Claire
Biswas, Pinaki
Valdez, Hernan
DiBonaventura, Marco
Nduaka, Chudy
Rojo, Ricardo
JAMA DERMATOLOGY, 2020, 156 (08) : 863 - 873

← 1 2 3 4 5 →